Generic drug substitution can markedly decrease the cost of health care. For conditions where agents have a relatively narrow therapeutic index, notably epilepsy, financial savings through generic ...

it is unlikely that the Food and Drug Administration will ever approve it for longevity. The agency doesn’t consider aging to ...

The U.S. Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals), a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to ...

The US Food and Drug Administration has approved a generic once-daily injectable version of the glucagon-like peptide-1 receptor agonist (GLP-1 RA) liraglutide (Victoza, Novo Nordisk) to lower ...